Arbutus Biopharma (NASDAQ: ABUS) reported Q4 EPS of ($0.46), $0.33 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $39 million versus the consensus estimate of $6.18 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.